• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.13% Nasdaq Down0.93%

    Medivation, Inc. (MDVN)

    104.25 0.47(0.45%) Jan 28, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Medivation, Inc.
    525 Market Street
    36th Floor
    San Francisco, CA 94105
    United States - Map
    Phone: 415-543-3470
    Fax: 415-543-3411
    Website: http://www.medivation.com

    Index Membership:N/A
    Full Time Employees:468

    Business Summary 

    Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Medivation, Inc.

    Corporate Governance 
    Medivation, Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 8. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 9; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. David T. Hung M.D., 57
    Founder, Chief Exec. Officer, Pres and Exec. Director
    Ms. Jennifer J. Rhodes , 45
    Gen. Counsel and Corp. Sec.
    Dr. Lynn Seely M.D., 56
    Chief Medical Officer
    Mr. Rick Bierly , 59
    Chief Financial Officer
    Ms. Anne Bowdidge ,
    Sr. Director of Investor Relations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders